News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investment entities affiliated with Squadron Capital Management LLC have reported a beneficial ownership of 7.0% in Relmada Therapeutics, Inc. This stake, amounting to 7,350,000 shares, is held by Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank, based on shares …
5 Must-Read Analyst Questions From Helmerich & Payne's Q2 Earnings Call Helmerich & Payne's latest quarter drew a positive market response as the company reported revenue above Wall Street's expectations, despite flat year-on-year sales. Management attributed the performance to increased rig reactivations in North …
This article provides a detailed overview of Elmet Group Ord Shs (Proposed) (ELMT) stock, including its current price, key figures, and analyst ratings. It highlights that ELMT is trading at $17.220 with a recent gain of 1.71% and has a "Buy" rating from analysts …
Needham Investment Management L.L.C., along with related entities and George A. Needham, have reported beneficial ownership stakes in Elmet Group Co. common stock, totaling 2,639,416 shares, which represents 8.8% of the common stock. All reported shares are held with shared voting and dispositive power …
The Elmet Group (NASDAQ: ELMT) reported strong Q2 2026 financial results, with adjusted earnings of $0.18 per share, significantly exceeding the $0.06 consensus estimate. Revenue grew 35.2% year-over-year to $66.4 million, driven by robust demand. The company also achieved a 25.0% gross profit margin …
The Elmet Group reported strong Q2 2026 results with a 35% revenue increase to $66.4 million, driven by demand in aerospace, defense, government, and industrial sectors, alongside effective strategic tungsten sourcing. The company achieved a 57.9% growth in adjusted EBITDA and a record backlog …
The Elmet Group Co. (NASDAQ:ELMT) announced strong financial results for its fiscal second quarter ended July 3, 2026, driven by accelerated demand in Aerospace, Defense & Government markets. The company reported a 35.2% increase in revenue to $66.4 million, a 430 basis point improvement …
Elmet Group Co. (ELMT) reported its 2026 quarter results, showing a significant revenue increase to $66.4 million from $49.13 million year-over-year. Despite this growth, the company recorded a net loss of $4.49 million and a negative diluted EPS of ($0.16) for the period. The …
This page provides a bond risk profile for ELME Communities' WRE.GL bond, specifically the 3.875% bond due September 15, 2026. It highlights key metrics for risk analysis, including security level, inflation protection, and issuer rating, to help users evaluate the bond's reliability. The article …
This article provides a key metrics profile for the Elme Communities (WRE.GL) 3.875% bond maturing on September 15, 2026. It details essential facts about the bond, including its issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The profile …
This page provides a detailed overview of Relmada Therapeutics Inc (RLMD) stock, including its current price, market capitalization, financial strength, growth, momentum, and profitability ranks. It also lists upcoming earnings dates, past stock events, and recent news articles related to the company's financial results …
This article lists various Exchange Traded Funds (ETFs) that invest in Helmerich & Payne, Inc. (HP) stocks, detailing their market value, weight in the fund, issuer, management style, focus, expense ratio, AUM, price, and 3-year total return. The ETFs listed primarily focus on small-cap …
This analysis of Elmet Group (ELMT) highlights its consistent revenue growth but mixed profitability and volatile cash flows. While its CMC segment benefits from strong aerospace and defense demand, the EMP segment faces margin compression. The company, trading below its fair value, recently completed …
Mizuho has reiterated an Outperform rating and $19.00 price target for Relmada Therapeutics Inc (NASDAQ:RLMD) despite concerns over manufacturing delays for its NDV-01 program. The stock has seen a significant decline since these concerns emerged, though it has surged over 700% in the past …
Several oil and gas stocks, including Helmerich & Payne, Range Resources, Valaris, Liberty Energy, and Seadrill, saw significant jumps following a rebound in Brent crude prices. This rise is attributed to geopolitical risk premiums staying high due to Strait of Hormuz negotiations and a …
This article first appeared on GuruFocus. Revenue (H1 2026): EUR314.5 million, up more than 15% year-over-year. Revenue (Q2 2026): EUR162 million, up 11% year-over-year and more than 6% sequentially. Gross Margin (H1 2026): 45.2%, an improvement of 3 percentage points year-over-year. Operating EBIT (H1 …
Helmerich & Payne (HP) shares are up nearly 12%, trading at $41.53, which would mark its highest close since May 2026 and its largest percentage increase since April 2025. The company has seen a significant surge recently, rising for three consecutive days and showing …
Helmerich & Payne (NYSE:HP) shares reached a new 52-week high after Barclays raised its price target from $47 to $50, maintaining an "overweight" rating. The stock traded as high as $41.88, significantly above its previous close of $37.10, despite analyst ratings being mixed with …
Helmerich & Payne (HP) surged 9.9% on August 10, 2026, closing at $40.77, driven by a sector-wide rally in the oil and gas drilling industry. The company's stock, along with peers like Patterson-UTI Energy and Noble Corporation, saw significant gains, indicating broad investor optimism …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Helmerich & Payne (HP) is back in focus after partnering with Formentera Partners, Daly Waters Energy and INPEX on a long term FlexRig …
Helmerich & Payne (H&P) saw strong performance in its fiscal third quarter, driven by increased drilling demand, particularly in the Permian Basin. Industrial Info Resources is tracking over $3 billion in projects featuring H&P's services, with a significant portion attributed to Devon Energy and …
Relmada Therapeutics (NASDAQ:RLMD) announced its quarterly earnings, reporting an EPS loss of $0.11, significantly beating analysts' expectations of a $0.20 loss by $0.09. Despite the positive earnings surprise and a strong financial position with $217.7 million in cash expected to fund operations through 2029, …
Piper Sandler analyst Kelsey Goodwin maintained a Buy rating on Relmada Therapeutics (RLMD) with a price target of $12.00, noting Goodwin's strong track record in the Healthcare sector. H.C. Wainwright also reiterated a Buy rating and a $12.00 price target for the stock. Relmada …
Key Points Interested in Helmerich & Payne, Inc.? Here are five stocks we like better. Helmerich & Payne exceeded fiscal Q3 2026 guidance across all three segments, with revenue above $1 billion, adjusted EBITDA of $236 million and free cash flow of $98 million. …
Helmerich & Payne, Inc. recently reported a surprise quarterly profit, prompting analysts to update their financial models. While the company's shares experienced a slight decline after the earnings release, analysts are now forecasting a significant increase in revenue and earnings per share for the …
Helmerich & Payne (HP) saw its stock rise by 9.8% following a return to profitability in Q3 2026 and securing a long-term contract with Formentera Partners for drilling in Australia's Beetaloo Basin starting in 2027. These developments highlight improving operational performance, increasing international demand …
Search by ticker symbol or company name and select a result to open its chart.